The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Non-Hodgkin Lymphoma Clinical Trial

— LEO  

Official title:

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02736357
• Other study ID #: 15-007282
• Status: Withdrawn
• Start date: July 1, 2015
• Est. completion date: April 17, 2023

Study information

• Verified date: June 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.

Description:

Newly diagnosed non-Hodgkin lymphoma (NHL) patients will be recruited from each center participating in the LEO cohort. At time of consent, participants will be asked to completed several questionnaires collecting health history, current medical and quality of life questions. Patients will also provide a baseline blood sample that will processed locally and stored centrally for future research use. Additionally, consent is given for use of excess clinical tumor tissue for research use.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 17, 2023
• Est. primary completion date: April 17, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment

• Patients may have been treated as long as initial NHL diagnosis is within 6 months of enrollment

• 18 years of age or older

Exclusion Criteria:

• Lymphoma diagnosis greater than 184 days from date of consent

Related Conditions & MeSH terms

• Lymphoma
• Non-Hodgkin Lymphoma

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of Iowa	Iowa City	Iowa
United States	University of Miami	Miami	Florida
United States	Weill Cornell Medical College	New York	New York
United States	Mayo Clinic	Rochester	Minnesota
United States	University of Rochester	Rochester	New York
United States	Washington University	Saint Louis	Missouri

Sponsors (8)

Lead Sponsor	Collaborator
Mayo Clinic	Emory University, M.D. Anderson Cancer Center, University of Iowa, University of Miami, University of Rochester, Washington University School of Medicine, Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	Time from date of diagnosis to date of death	Short (<5 years), medium (5-10 years), and long-term (>10 years)
Secondary	Event Free Survival (EFS)	Time from date of diagnosis to date of first defined event (disease progression, relapse or re-treatment for lymphoma, or death)	Short (<5 years), medium (5-10 years), and long-term (>10 years)
Secondary	Lymphoma Specific Survival (LSS)	Time from date of diagnosis to date of death due to lymphoma	Short (<5 years), medium (5-10 years), and long-term (>10 years)

External Links

•   Mayo Clinic Clinical Trials